Mutations in the gene JAGN1 were recently discovered in patients with severe congenital neutropenia (SCN). Neutrophils release neutrophil extracellular traps (NETs) consisting of decon- 
INTRODUCTION
Neutrophils are the most abundant immune cells in the bloodstream and form the first line of cellular defense against microorganisms such as bacteria and fungi. 1 The key role of neutrophils is underscored by the fact that individuals with decreased numbers of neutrophils suffer from recurrent, life-threatening infections. 2 Neutrophil granulocytes are the first cells to reach the site of infection, where they deploy a range of different antimicrobial mechanisms including phagocytosis, Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; COPI, coat protein I; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte/macrophage colony-stimulating factor; JAGN1, Jagunal homolog 1; MDS, myelodysplastic syndrome; MOI, multiplicity of infection; MPO, myeloperoxidase; NE, neutrophil elastase; NETs, neutrophil extracellular traps; PMA, phorbol 12-myristate 13-acetate; SCN, severe congenital neutropenia
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. with intracellular proteolytic and oxidative destruction of pathogens, or release of granule enzymes such as neutrophil elastase (NE) and myeloperoxidase (MPO), along with antibacterial peptides, or to the pharmacological agent, phorbol 12-myristate 13-acetate (PMA), 6, 7 a known activator of the NADPH oxidase, and while this is the most common way of triggering NETs ex vivo, recent work has shown that different stimuli engage different pathways of NET production and release. 8, 9 NETs also participate in sterile foreign body responses. 10 Phagocytes (macrophages and neutrophils) are a primary mode of defense against fungal pathogens 11 and fungal infections are common in patients with impaired neutrophil function. 12 However, the physical size of fungal cells presents a problem for the host immune system. Fungal yeast cells typically range from 5 to 10 m, while hyphae are considerably longer. It is therefore of interest to note that Candida albicans, the predominant etiologic agent of fungal infections in humans, particularly in immunocompromised hosts, induces NET formation and is susceptible to NET-mediated killing, potentially circumventing the need for phagocytosis. 13 Indeed, Branzk et al. 14 provided evidence that neutrophils could 'sense' microbe size and selectively release NETs in response to large pathogens, such as C. albicans hyphae, but not in response to small yeast or bacteria. Size-tailored neutrophil responses may serve to minimize the pathology resulting from excessive production of NETs. Furthermore, neutrophils were shown to trigger unmasking of fungal pathogens through NET-mediated remodeling of the fungal cell wall, leading to macrophage recognition. 15 Aspergillus fumigatus, another important human pathogen, was also found to induce NET formation in vivo, but NETs did not seem to contribute to killing of this fungus, though they could have a fungistatic role and prevent dissemination of the pathogen. 16 Severe congenital neutropenia (SCN) denotes a heterogeneous group of diseases causing early-onset life-threatening susceptibility to microbial infections accompanied by lack of mature neutrophils. 17 Myeloid progenitor cells from patients with CN display an elevated degree of apoptosis; this is counteracted by G-CSF. 18, 19 Studies from multiple laboratories have identified mutations in the ELA2, HAX1, G6PC3, WAS, and GFI1 genes in patients with different forms of CN. [20] [21] [22] [23] [24] [25] More recently, Boztug et al. 26 reported the discovery of homozygous mutations in the gene encoding Jagunal homolog 1 (JAGN1) in individuals with SCN. JAGN1-mutant granulocytes are characterized by a paucity of granules, aberrant N-glycosylation of multiple proteins, and increased apoptosis, with some evidence of ER stress. The authors also noted that the response to recombinant G-CSF treatment was poor in several JAGN1-deficient individuals. 26 Moreover, mice carrying a hematopoietic lineage-specific deletion of Jagn1 were found to be unable to mount an efficient immune response to C. albicans. 27 Jagn1-deficient bone marrow neutrophils were defective for MPO release following incubation with C. albicans. The latter study showed that Jagn1 (JAGN1 in humans) is an important regulator of the antimicrobial function of neutrophils. However, whether JAGN1 is required to produce NETs has not been studied. Here we asked whether JAGN1 is required for NET formation and/or antifungal activity using neutrophil-like HL-60 cells and neutrophils from a patient with JAGN1 mutations. JAGN1 was required for MPO expression in NETs, but not for NET release, and the killing of C. albicans in NETs was dependent on JAGN1 expression.
PATIENT AND METHODS

Patient history
A boy born in 2006, the youngest child with four healthy siblings to parents of consanguineous marriage, was admitted to the Karolinska University Hospital, Stockholm at the age of 2 years. During the neonatal period, he had an umbilical infection and during the first years of life frequent episodes of bronchitis and pneumonia. Neutropenia, ANC < 0.5 × 10 9 /L, was observed and bone marrow examination showed maturation arrest of the myelopoiesis, but this was initially interpreted as autoimmune neutropenia. However, pro-LL-37 in plasma was only 1% of control, which is seen only in SCN. 28 The patient was diagnosed with severe congenital neutropenia (SCN). Mutational analyses of the ELANE and HAX1 genes showed no causative defects.
Treatment with recombinant G-CSF commenced at 2½ years of age and ceased at the age of 9 years due to increased resistance to treatment. Homozygous mutations in JAGN1 were identified by exome sequencing and verified by direct sequencing (to be reported elsewhere). The patient is currently (December 2017) scheduled for a bone marrow transplantation due to resistance to G-CSF and problems with infections including severe periodontitis. Peripheral blood samples were collected in connection with the annual follow-up that is conducted in SCN patients due to the risk of secondary MDS/AML. 29 We could not, however, collect further blood samples for evaluation of fungal killing. The study was approved by the Regional Ethical Committee in Stockholm, Sweden, and informed consent was obtained from the parents.
Neutrophil isolation
Neutrophils were isolated from freshly drawn peripheral blood of the patient or a healthy control (Karolinska University Hospital, Stockholm, Sweden) using density gradient centrifugation with Lymphoprep (Axis-Shield, Norway) as previously described. 30 Then, a further gradient sedimentation in 5% dextran solution was performed to separate neutrophils from erythrocytes, and residual erythrocytes were removed by hypotonic lysis. Freshly isolated neutrophils were maintained in 5% CO 2 at 37 • C in phenol red-free RPMI-1640 medium (Gibco) supplemented with 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin, and used immediately for experiments.
HL-60 cell culture
The human acute promyelocytic leukemia cell line HL-60 (ATCC -CCL-240) was maintained in phenol red-free RPMI-1640 medium supplemented with 2 mM L-glutamine and 10% heat-inactivated FBS (Sigma) in 5% CO 2 at 37 • C. In order to allow for neutrophil-like differentiation, the cells were seeded at 0.5 × 10 6 cells/mL in the above-mentioned cell medium supplemented with 1.25% DMSO for 5 days, as described, 31 changing the medium after 3 days.
JAGN1 overexpression
HL-60 cells were transiently transfected with N-terminal FLAGtagged JAGN1 constructs for overexpression experiments. Cells were stimulated to undergo neutrophil-like differentiation as described 
NET production and quantification
In order to stimulate differentiated HL-60 cells to produce NETs, cells were seeded at a density of 2.5 × 10 6 cells/mL in phenol red-free RPMI-1640 medium supplemented with 2 mM L-glutamine in the absence of FBS and stimulated with 50 nM PMA for 3 h in 5% CO 2 at 37 • C.
Cell medium was then collected through extensive pipetting and centrifuged at 1600 rpm for 5 min, and NET-containing supernatants were retrieved and used for further assays. For quantification of NETs, the SYTOX green assay was utilized. 32 To this end, HL-60 cells were seeded in HBSS in a black 96-well plate at a density of 0.1 × 10 6 cells/well and incubated in the presence or absence of 50 nM PMA for 3 h in 5% CO 2 at 37 • C. As a control, samples were either subjected to digestion for 45 min with DNAse I (5 g/mL) or treated with 10% TritonX for 45 min.
SYTOX green (5 M) was added to the samples, and incubation was performed for a further 15 min prior to quantification of fluorescence emission at 523 nm with an Infinite F200 Tecan plate reader (Männen-dorf, Switzerland). Simultaneously, DNA content of purified NETs was measured using NanoDrop TM spectrophotometer (NanoDrop 1000; Thermo Scientific) and data were recorded using ND-1000 V3.6.0.
software and displayed as g/mL. Oberkochen, Germany), as described previously. 30 Briefly, a Zeiss LSM 510 Confocal Microscope was used. Single field images of 1024 × 1024 pixels were collected using a 543 nm HeNe laser to visualize MPO and Ar/ML 458/488/514 nm argon laser to visualize SYTOX-identified DNA along with DAPI in which the fixed samples were mounted. Due care was taken while obtaining the images in that lamp intensity, exposure time and pinhole parameters were maintained constant among different samples and experiments. Images were scanned and analyzed using LSM image browser (Zeiss) keeping the settings similar throughout the analysis and among the samples.
NET visualization
Western blot analysis
For western blot analysis, the following Abs were used: rabbit polyclonal anti-MPO (Abcam), rabbit polyclonal anti-human NE (Calbiochem), mouse monoclonal anti--actin (Sigma-Aldrich), mouse monoclonal anti-FLAG (Sigma-Aldrich), and secondary anti-mouse or anti-rabbit fluorescently labeled Ab (LI-COR Biosciences). Whole cell lysate was obtained through lysis of a defined number of cells in lysis buffer followed by sonication. For HL-60 cells, lysis buffer CellLytic M (Sigma-Aldrich) was used, whereas, for primary neutrophils, modified RIPA containing 50 mM HEPES (pH 7.6), 75 mM NaCl, 0.25% Na-deoxycholate, 1% NP-40, 0.1% SDS,1 mM EDTA,1 M NaF, 5 mM MgCl2 was used with 100 M sodium orthovanadate, 900 M benzamidine,1 mM phenantroline, 2 mM phenylmethylsulfonyl fluoride inhibitor cocktail added just before the lysis. For western blot of purified NETs, NETs were pretreated with DNase I (5 g/mL) for 1 h at 37 • C in order to digest the DNA prior to loading onto gels. Proteins were separated on 4-20% Tris-Glycine gradient gels (Invitrogen) by electrophoresis under reducing conditions and the blots were probed overnight at 4 • C followed by secondary Ab incubation and washing.
Blots were scanned and imaged using the LI-COR Biosciences system following the manufacturer's instructions.
MPO glycosylation
Differentiated HL-60 cells were seeded in 24-well plates and transfected with either control siRNA or JAGN1-specific siRNAs 1 or 2 as described above. For glycosylation studies, the cells were lysed with buffer containing 20 mm Tris-HCl (pH 7.4), 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 5 mm NaF, 1 mm orthovanadate, 10% glycerol, 1% Triton X-100, 0.5% Nonidet P-40 and protease inhibitors, 48-72 h post transfection and the cleared protein lysate was either non-treated or treated with EndoH or PNGase F (New England Biolabs). Samples were then subjected to western blot using the rabbit anti-MPO Ab as primary Ab. -Actin was used as a loading control. To verify MPO glycosylation in primary neutrophils, lysates were prepared from peripheral blood neutrophils from patient or control and lysates were either treated with EndoH and PNgase F or left untreated and subjected to MPO detection by western blot as above.
Enzyme linked immunosorbent assay
MPO and calprotectin protein was quantified in cell lysates and/or in purified NETs obtained from HL-60 cells using MPO ELISA (eBioscience/Affymetrix) and calprotectin ELISA (Nordic BioSite, Täby, Sweden), respectively following the manufacturer's instructions.
MPO activity
MPO activity was assessed using the MPO activity assay kit (abcam) following the manufacturer's instruction. Total cell lysates were prepared in the buffer provided in the kit. 
Flow cytometry
Statistics
One-way analysis of variance (ANOVA) with Newman-Keuls posttest was applied when multiple groups were compared and two-tailed Student's t-test was used for analysis of 2 groups. For nonparametrically distributed data, the two-tailed Mann-Whitney test was used. Differences were considered statistically significant at P < 0.05. All statistical tests were performed using GraphPad Prism version 5.0 and/or MS Excel 2016. Level of significance indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
RESULTS
JAGN1 is dispensable for PMA-induced NET release
Homozygous mutations in JAGN1 were recently shown to be causative of SCN. 26 Moreover, Jagn1 deficiency in mice resulted in an inefficient neutrophil-dependent immune response to C. albicans. 27 Since NETs have been reported to play a role in fungal killing, we aimed to determine whether JAGN1 is required for the formation and/or function of NETs. We first tested whether peripheral blood neutrophils obtained from a patient with JAGN1 mutations (c.40G > A; p.Gly14Ser) were capable of producing NETs ex vivo in response to PMA, a commonly used trigger of NETs. Neutrophils from a healthy donor were included for comparison. As seen in Fig. 1A, PMA (25 nM) elicited a vigorous response both in patient and donor cells. For comparison, unstimulated donor and patient cells are also shown.
NETs were visualized using Abs directed against MPO and NE along with DAPI. Based on this morphological assessment, NET formation in cells from the JAGN1-deficient patient and healthy donor appeared comparable in terms of NE and/or DAPI staining; however, there appeared to be a lower amount of MPO on patient-derived NETs (Fig. 1A) . Using a specific ELISA, we found that the amount of MPO was reduced in cell lysates from patient cells when compared to control cells (Fig. 1B) . Furthermore, western blotting of cell lysates was suggestive of a reduced amount of MPO in the JAGN1-deficient patient (Fig. 1C,D) , though it is noted that the healthy donor was not age-matched. To exclude the possibility that the differences between the patient and the healthy donor are due to interindividual variations, we tested 3 additional donors with respect to NET formation and MPO expression and found no significant differences (Supplementry Fig.   1A -E). Taken together, these data showed that JAGN1 deficiency in the patient whom we have studied here does not prevent the release of NETs in ex vivo activated human neutrophils. It is also worth noting that while JAGN1 deficiency is associated with increased susceptibility to apoptosis, 26 PMA-induced NADPH oxidase activation does not lead to apoptosis, 33 and apoptosis is therefore unlikely to play a role in the release of NETs under these conditions.
To corroborate these findings, and in order to study the role of JAGN1 in more detail, we utilized HL-60 cells as a model. HL-60 cells are known to differentiate into neutrophil-like cells in response to a variety of chemical stimuli. 34 We developed a protocol for neutrophillike differentiation and simultaneous down-regulation or overexpression of JAGN1. Hence, HL-60 cells were transfected with either JAGN1 specific siRNA or FLAG-tagged JAGN1 constructs to downregulate and overexpress JAGN1, respectively ( Fig. 2A,B) . To verify the neutrophil-like phenotype, we examined CD11b expression and nuclear morphology of differentiated HL-60 cells. Using different stimuli (DMSO, DMF, and ATRA) (data not shown), we observed that 1.25% DMSO treatment for 5 days rendered maximal CD11b expression as confirmed by flow cytometry (Supplementry Fig. 2A ) and multilobular nuclear morphology as shown by fluorescence microscopy (Supplementary Fig. 2B ). Moreover, we confirmed that JAGN1 silencing had no effect on the differentiation of HL-60 cells to neutrophil-like cells based on the same parameters (Supplementry Fig. 2C,D) . We then asked whether down-regulation or overexpression of JAGN1 affected the release of NETs. Differentiated cells were stimulated with PMA (50 nM) for 3 h, at which time NET formation was quantified by using the SYTOX green assay to detect extracellular DNA. PMA caused a comparable increase in NET production both in control siRNA and JAGN1 siRNA transfected cells (Fig. 2C) . Then, we visualized NETs by confocal microscopy. While nontransfected neutrophil-like cells and cells in which JAGN1 had been silenced or overexpressed all displayed a similar response to PMA as evidenced by SYTOX green staining (Fig. 2D) , we noted remarkable differences in MPO content, with significantly diminished MPO staining in NETs following JAGN1 silencing (Fig. 2D) . To ensure that the production of NETs in response to PMA was comparable between control siRNA and JAGN1 siRNA transfected cells, we quantified NETs using the SYTOX green assay as well as the NanoDrop TM spectrophotometer ( Supplementary Fig. 3A,B) and found that the level of NETs, as determined on the basis of DNA content, was consistent between the different conditions, and showed little variation between experiments. Together, these data showed that JAGN1-silenced, neutrophil-like HL-60 cells remain capable of releasing NETs in response to PMA; however, our results showed that JAGN1 promotes the expression of MPO in NETs.
JAGN1 regulates neutrophil expression of MPO
To further investigate impact of JAGN1 on MPO expression, we downregulated JAGN1 in differentiated HL-60 cells (Fig. 3A) and determined the level of MPO mRNA expression. MPO transcripts were significantly decreased in JAGN1 down-regulated cells (Fig. 3B) . Similarly, MPO protein levels were also reduced in JAGN1 silenced cells as measured by ELISA (Fig. 3C ) and immunoblot analysis (Fig. 3D) . Both heavy chain and light chain MPO were affected and the cumulative band density was significantly decreased in JAGN1 silenced cells when compared to cells transfected with control siRNA (Fig. 3E) . Our data thus suggest that JAGN1 regulates MPO mRNA and protein levels. We also is known to be required for optimal enzymatic activity. 35 We asked whether JAGN1 silencing in neutrophil-like HL-60 cells would influence N-glycosylation of MPO. However, N-glycosylation of MPO was not affected by JAGN1, as shown by the treatment of cellular extracts with endoglycosidase H (EndoH) and peptide N-glycosylase (PNGase) for deglycosylation (Fig. 3F) . Furthermore, GM-CSF (100 ng/mL) did not affect the N-glycosylation pattern. We also studied N-glycosylation in peripheral blood neutrophils from the JAGN1-deficient patient and found no aberrations when compared to a healthy donor, though MPO expression was significantly lower in patient cells (Fig. 3G ) (note that more protein was loaded to visualize MPO in the patient samples). 25% DMSO into neutrophil-like cells with or without JAGN1 silencing were exposed to PMA (50 nM) or left untreated for 3 h at 37 • C. SYTOX green assay was performed to quantify NET production (and see Supplementary Fig. 3A-B) . Results shown as mean values ± SD (n = 3). *P ˂ 0.05; **P ˂ 0.01; ****P < 0.0001. (D) Detection of NETs using confocal microscopy. Neutrophil-like HL-60 cells (nontransfected, or transfected with scrambled siRNA or JAGN1 siRNA or FLAG-tagged JAGN1) were stimulated or not with PMA (50 nM) for 3 h at 37 • C and immunostained for MPO (red), and DNA (SYTOX green). The experiment was performed 3 times and representative images from at least 20 images per sample are depicted. For a higher magnification view of unstimulated cells transfected with scrambled siRNA or JAGN1 siRNA, refer to Supplementary Fig. 4E 
GM-CSF restores MPO expression in NETs
G-CSF is used successfully to treat patients suffering from CN. 36 However, while G-CSF leads to an increased number of functional neutrophils in CN patients, 38 GM-CSF fails to increase neutrophil numbers and instead induces increased numbers of monocytes and eosinophils in CN patients. 39 On the other hand, Wirnsberger et al. 27 recently reported that GM-CSF restored the fungicidal activity of bone marrow cells derived from patients with JAGN1 mutations.
We tested, therefore, whether GM-CSF treatment altered/restored (Fig. 4A) . To verify these morphological observations, we purified NETs as previously described 30 and quantified the level of MPO in NETs by ELISA. GM-CSF resulted in a complete recovery of MPO expression in NETs (Fig. 4B) . These results were confirmed by western blot analysis of purified NETs.
GM-CSF treatment resulted in a recovery of the expression of heavy and light chain MPO ( Supplementary Fig. 4A-C) .
It is conceivable that other factors aside from MPO also contribute to the candidacidal activity evidenced in the present model. Indeed, calprotectin was previously reported to be required for clearance of C.
albicans infections, and a proportion of calprotectin was shown to be bound to NETs. 37 We therefore determined calprotectin levels both in purified NETs from control siRNA and JAGN1 siRNA transfected cells treated with PMA and in non-stimulated cells (Fig. 4C and D) . 
Fungal killing in NETs requires MPO expression
More than a decade ago, Urban et al. 13 reported that C. albicans triggered NETs and showed that NETs could trap as well as kill C. albicans.
Here, we asked whether silencing of JAGN1 would impact on the candidacidal function of neutrophil-differentiated HL-60 cells. To elucidate the role of NETs, we also determined killing of C. albicans in the presence or absence of DNaseI. As shown in Fig. 5A and B, by using confocal microscopy, both yeast and hyphal forms of C. albicans triggered NETs, in line with previous studies. 37 Notably, we observed release of NETs F I G U R E 5 NETs are needed for efficient killing of C. albicans by HL-60 cells. Control siRNA or JAGN1 specific siRNA transfected HL-60 cells were seeded on poly-L-lysine coated slides followed by incubation with hyphae (A) or yeast (B) at MOI 0.01 for 2 h at 37 • C. After incubation, cells were washed, fixed and stained with SYTOX green and Calcofluor to detect extracellular DNA (NETs) and fungi, respectively, and analyzed by confocal microscopy. Representative images of at least 20 images/sample are shown. Simultaneously, cells transfected with control siRNA or JAGN1 siRNA were pretreated or not with DNase I (100 U/mL) for 1 h prior to infection with yeast (C) or hyphae (D) for 2 h at 37 • C. Fungal killing was determined by assessment of colony-forming units. The results are shown as mean values ± SD (n = 3). *P ˂ 0.05; **P ˂ 0.01 in both JAGN1 silenced and control transfected cells exposed to C. albicans. Moreover, killing of C. albicans (yeast and hyphae) was drastically reduced in cells transfected with JAGN1 siRNA (Fig. 5C and D) . Cells were infected at a multiplicity of infection (MOI) of 0.01. The killing of C. albicans was further reduced in the presence of DNaseI (100 U/mL), thus implicating NETs. The latter effect was pronounced but did not reach statistical significance for yeast while the effect of DNaseI on the killing of hyphae was significant.
Next, we asked whether NETs purified from control siRNA or JAGN1 siRNA transfected cells were able to kill C. albicans. Purified NETs were used in order to exclude phagocytic killing and/or degranulation. The fungal culture was optimized to yield a pure population of yeast or hyphae, and this was confirmed by conventional light microscopy ( Fig. 6A ). We then coincubated purified NETs obtained (Fig. 6B-E) . The addition of H 2 O 2 alone had no effect on C. albicans (data not shown). Fungal killing was restored when NETs derived from cells pretreated with GM-CSF (100 ng/mL) were used.
Moreover, preincubation of NETs with MPO (2.5 g/mL; 0.066 M) completely restored the candidacidal capacity of NETs derived from JAGN1 silenced cells (Fig. 6B-E ).
DISCUSSION
JAGN1 encodes the human homolog of Jagunal, identified as an ER membrane protein in Drosophila melanogaster. 40 Jagunal was suggested to be involved in ER reorganization and vesicular trafficking during Drosophila oogenesis. Jagunal is also responsible for the asymmetric ER partitioning during mitosis in the Drosophila embryo. 41 Moreover, recent studies in transgenic mice showed that Jagn1 is required to mount an efficient immune response to C. albicans. 27 Importantly, homozygous mutations in JAGN1 were recently shown to cause SCN, characterized by an increased risk of life-threatening infections. 26 Neutrophils are key players in the host defense against fungal pathogens 11 and MPO is required for the candidacidal activity of human neutrophils. 42 C. albicans triggers NETs both in primary neutrophils and in neutrophil-like HL-60 cells and is susceptible to NETmediated killing. 13, 37, 43 In the present study, we explored the potential role of JAGN1 in the formation and antifungal function of NETs. The presence of antimicrobial factors such as histones and granule proteins can mediate direct interaction with pathogens in NETs. 11 In particular, binding of NET-bound MPO to microorganisms is known to result in the production of hypochlorous acid in close proximity to the trapped microorganisms increasing the possibility that the microorganism is destroyed by this highly reactive product of MPO. 45 Thus, the production of NETs in response to C. albicans marks the first step 46 In the present study, NET formation and release was evidently unperturbed in JAGN1-silenced cells despite the decrease in the total cellular content of MPO. However, it is noted that MPO expression was not completely lost. Indeed, while neutrophils from donors who are completely deficient in MPO fail to form NETs, neutrophils from partially MPO-deficient donors remain capable of making NETs. 44 In a recent study, it was suggested that MPO is required for the release of NE during NET formation. 7 It is pertinent that the azurophilic granules, containing both MPO and NE, are often viewed as the 'lysosomes of neutrophils' 3 ; the release of NE during NETosis appears to share similarities with the release of lysosomal cathepsins during apoptosis. 7 MPO, a heme protein, is a major component of azurophilic granules of neutrophils. 3 The precursor protein undergoes cotranslational N-glycosylation, interactions with molecular chaperones, and heme incorporation in the ER to generate enzymatically active proMPO. 47 The added oligosaccharides contribute to the interactions with calreticulin and calnexin, 48, 49 whose role it is to promote proper folding and quality control of glycoproteins. The proMPO protein is then exported to the Golgi whereupon further processing takes place prior to the storage of MPO in azurophilic granules. 47 Recent studies have revealed that homozygous mutations in the calreticulin gene (CALR) lead to acquired MPO deficiency; these individuals have reduced MPO protein, but normal MPO mRNA levels, supporting a posttranscriptional defect in MPO production. 50 Further studies are required to Donini et al. 51 showed that MPO was absent or poorly expressed in neutrophils of SCN patients receiving treatment with G-CSF. They also found that cells from one SCN patient were defective for killing of C. albicans. The authors argued, therefore, that G-CSF is not sufficient to correct all of the functional deficiencies of neutrophils. 51 Notably, incubation of bone marrow neutrophils with GM-CSF, but not G-CSF, rescued the impaired MPO release of Jagn1-deficient murine neutrophils and restored their ability to kill C. albicans. 27 In the latter study, GM-CSF was also shown to restore antifungal cytotoxicity in bone marrow cells derived from 2 JAGN1-deficient SCN patients. Our present results are in agreement with these findings and show for the first time that GM-CSF can restore NET functionality by restoring MPO expression. In addition, other antifungal factors including calprotectin may also play a role.
Using rat INS-1 insulinoma cells as a model of pancreatic -cells, Nosak et al. 52 reported that Jagn1 regulates proinsulin biosynthesis.
The mechanism was not disclosed, but the authors speculated that Jagn1 could modulate the translation of abundant mRNAs by sequestering ribosomal subunits. 52 Furthermore, using HEK293 cells as a model, Boztug et al. 26 identified several members of the coat protein I (COPI) complex as potential interaction partners of JAGN1. The COPI complex plays a key role in vesicular trafficking within the Golgi complex and from the Golgi back to the ER. 53 It will be of considerable interest to determine whether JAGN1 interacts with the COPI complex in primary neutrophils or neutrophil-like cells, and whether this could explain how JAGN1 regulates the release of MPO and perhaps other proteins of azurophilic granules. It is also notable that Rab27a, a component of the secretory machinery of azurophilic granules, was recently shown to regulate GM-CSF-dependent priming of neutrophil exocytosis. 54 Interestingly, Rab27a is required for NET formation in PMA-and C. albicans-induced neutrophil-like HL-60 cells and in primary neutrophils. 43 In conclusion, we have shown that JAGN1 is dispensable for the release of NETs, extracellular, web-like structures consisting of nuclear chromatin, but required for NET-mediated killing of C. albicans; in the absence of JAGN1, MPO expression in NETs is severely reduced. We also observed that GM-CSF restored MPO expression in NETs and enabled efficient killing of C. albicans yeast and hypae.
These findings are in accordance with the recent observation that Jagn1 is a key regulator of antifungal host defense in mice, 27 and underscore the role of NETs in fungal killing. SCN patients are at risk of bacterial and fungal infections 55 and this may be particularly relevant for patients harboring JAGN1 mutations who, at least in some cases, appear to respond poorly to G-CSF treatment. 26 
